Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from BeiGene Ltd ( (HK:6160) ) is now available.
BeOne Medicines Ltd., a Swiss corporation, has issued an overseas regulatory announcement regarding a post-effective amendment to Form S-4, which has been filed with the U.S. Securities and Exchange Commission. This announcement, made under the rules governing the listing of securities on The Stock Exchange of Hong Kong Limited, indicates administrative updates in compliance with regulatory requirements, potentially impacting the company’s operational transparency and regulatory adherence.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,789,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$236.3B
For detailed information about 6160 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue